先期化疗联合术后腹腔热灌注化疗治疗晚期卵巢癌疗效观察

Clinical efficacy of neoadjuvant chemotherapy combined with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy after operation on advanced ovarian cancer

目的探讨先期化疗(NACT)联合肿瘤细胞减灭术(CDS)术后腹腔热灌注化疗(CIHCP)治疗晚期卵巢癌的临床疗效。方法将60例晚期卵巢癌的患者分为两组,观察组术前予以NACT 2个疗程,之后行CDS及术后IHCP(顺铂80 mg)2次,术后再予卡铂/顺铂(TC/TP)方案化疗,对照组采取常规CDS+术后TC/TP方案化疗,比较两组患者手术中腹水量、出血量、手术时间、术后并发症、术后化疗疗程、总有效率和生存率的差异。结果观察组患者术中和术后疗效优于对照组,差异有统计学意义(P<0.05),临床治疗总有效率高于对照组。结论对于晚期卵巢癌患者,NACT+CDS+IHCP疗效较常规方法有较大的提高。

[Objective] To investigate the clinical efficacy of neoadjuvant chemotherapy combined with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy （IHCP） after operation on advaneed ovarian cancer. [Methods ] Sixty patients with advanced ovarian cancer in the People＇s Hospital of Zhengzhou between April 2009 and July 2012 were divided into two groups. The research group was treated with two courses of neoadjuvant chemotherapy combined with eytoreductive surgery and IHCP twice （eisplatin 80 mg）, then given chemotherapy （TC/TP）, while the control group underwent primary cytoreduetive surgery and then chemotherapy （TC/TP）. The differences in operation time, bleeding volume, volume of ascites, postoperative chemotherapy, etc. were compared between both groups （P〈 0.05）. [Results] The treatment of the observation group was more effective than that of the control group, all the intraoperative and postoperative indicators showed significant differences （P 〈 0.05）. [Conclusion] Compared with conventional methods, the efficacy is greatly improved for patients with advanced ovarian cancer treated with neoadjuvant chemotherapy combined with eytoreductive surgery and IHCP.